Additional Characteristics of the Prostate Cancer Screening Decision-Making Process
| Characteristic | Control Group (n = 75) | Brochure Group (n = 196) | Web Site Group (n = 226) |
|---|---|---|---|
| PSA = prostate-specific antigen; DCS = Decisional Conflict Scale. | |||
| * Control group: patient-reported vs physician-reported frequency of PSA testing (P = .06). | |||
| † Physician-reported frequency of PSA testing: brochure group vs control group (P = .04). | |||
| ‡ Physician-reported frequency of PSA testing: Web site group vs control group (P = .06). | |||
| § Potential range: 0 to 10. | |||
| || Control vs brochure group (P <.001); control vs Web site group (P <.001). | |||
| Patients reported reviewing educational material before visit, % | 46 | 88 | 85 |
| PSA test ordered | |||
| Patient report, % | 85 | 83 | 86 |
| Physician report, % | 94* | 85† | 86‡ |
| Relative frequency no time (0 minutes) was spent discussing prostate cancer | |||
| Patient report, % | 2.7 | 1.0 | 3.1 |
| Physician report, % | 1.3 | 0.5 | 0.9 |
| Minutes spent discussing prostate cancer | |||
| Patient report, mean (range) | 5.2 (0–20) | 5.3 (0–25) | 5.1 (0–15) |
| Physician report, mean (range) | 4.2 (0–30) | 3.8 (0–15) | 3.7 (0–20) |
| Number of prostate cancer topics discussed§ | |||
| Patient report, mean (range) | 4.3 (0–10) | 4.9 (0–10) | 5.0 (0–10) |
| Physician report, mean (range) | 5.2 (0–10) | 5.1 (0–10) | 5.0 (0–10) |
| Percentage of knowledge questions patient answered correctly | 54|| | 69 | 69 |
| Patient DCS score, mean (range) | 1.58 (1–3.2) | 1.54 (1–2.8) | 1.55 (1–2.7) |